Verteporfin Photodynamic Therapy Cohort Study. Report 2: Clinical Measures of Vision and Health-Related Quality of Life

Ophthalmology

Volumn 116, Issue 12, 2009, Pages 2463-2470

  Reeves, Barnaby C ^b   Langham, Julia ^b   Walker, Jemma ^b   Grieve, Richard ^b   Chakravarthy, Usha ^c   Tomlin, Keith ^b   Carpenter, James ^b   Guerriero, Carla ^b   Harding, Simon P ^a  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VERTEPORFIN;

ARTICLE; COHORT ANALYSIS; CONTRAST SENSITIVITY; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; NATIONAL EYE INSTITUTE VISUAL FUNCTION QUESTIONNAIRE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RETINA MACULA AGE RELATED DEGENERATION; SHORT FORM 36; UNITED KINGDOM; VISUAL ACUITY;

EID: 70549098926     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2009.10.031     Document Type: Article

References (33)

1. Bren L. The importance of patient-reported outcomes ... it's all about the patients. FDA Consum 40 (2006) 26-32
2. Department of Health. Publications policy and guidelines. Guidance on the routine collection of Patient Reported Outcome Measures (PROMs) (for the NHS in England in 2009/10. 2008. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_092647 Accessed October 4, 2009
3. Bradley C. Importance of differentiating health status from quality of life. Lancet 357 (2001) 7-8
4. Mangione C.M., Lee P.P., Gutierrez P.R., et al., National Eye Institute Visual Function Questionnaire Field Test Investigators. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol 119 (2001) 1050-1058
5. EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 16 (1990) 119-208
6. Brazier J., Roberts J., and Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 21 (2002) 271-292
7. Brazier J., Ratcliffe J., Tsuchiya A., and Salomon J.A. Measuring and Valuing Health Benefits for Economic Evaluation (2007), Oxford University Press, Oxford, England 7-36
8. In: Gold M.R., Siegel J.E., Russell L.B., and Weinstein M.C. (Eds). Theoretical foundations of cost-effectiveness analysis. Cost-Effectiveness in Health and Medicine (1996), Oxford University Press, New York 82-134
9. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal (June 2008) 1-80. http://www.nice.org.uk/aboutnice/howwework/devnicetech/technologyappraisalprocessguides/guidetothemethodsoftechnologyappraisal.jsp Accessed October 4, 2009
10. Stelmack J. Quality of life of low-vision patients and outcomes of low-vision rehabilitation. Optom Vis Sci 78 (2001) 335-342
11. Margolis M.K., Coyne K., Kennedy-Martin T., et al. Vision-specific instruments for the assessment of health-related quality of life and visual functioning: a literature review. Pharmacoeconomics 20 (2002) 791-812
12. Brown G.C., Sharma S., Brown M.M., and Kistler J. Utility values and age-related macular degeneration. Arch Ophthalmol 118 (2000) 47-51
13. Colquitt J.L., Jones J., Tan S.C., et al. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation. Health Technol Assess 12 (2008) iii-iv, ix-201
14. Harding S.P., Tomlin K., Reeves B.C., et al., VPDT study group. Verteporfin Photodynamic Therapy Cohort study. Report 1: Effectiveness and Factors Influencing Outcomes. Ophthalmology 116 (2009) e1-e8
15. Grieve R., Guerriero C., Walker J., et al., VPDT study group. Verteporfin Photodynamic Therapy Cohort study. Report 3: Cost effectiveness and Lessons for Future Evaluations. Ophthalmology 116 (2009) 2471-2477
16. Ware Jr. J.E., and Sherbourne C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30 (1992) 473-483
17. The Verteporfin Photodynamic Therapy Cohort Study for the United Kingdom. Manual of Operations version 2.1 (December 2005) 79-83. http://www.lshtm.ac.uk/hsru/vpdt/publications/Manop_v21_211205.pdf Accessed October 4, 2009
18. Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics: ETDRS report number 7. Ophthalmology 98 suppl (1991) 741-756
19. Pelli D.G., Robson J.G., and Wilkins A.J. The design of a new letter chart for measuring contrast sensitivity. Clin Vis Sci 2 (1988) 187-199
20. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials. TAP report 2. Arch Ophthalmol 119 (2001) 198-207
21. Rosenfeld P.J., Brown D.M., Heier J.S., et al., MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1419-1431
22. Brown D.M., Kaiser P.K., Michels M., et al., ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1432-1444
23. Bansback N., Czoski-Murray C., Carlton J., et al. Determinants of health related quality of life and health state utility in patients with age related macular degeneration: the association of contrast sensitivity and visual acuity. Qual Life Res 16 (2007) 533-543
24. Submacular Surgery Trials Research Group. Evaluation of minimum clinically meaningful changes in scores on the National Eye Institute Visual Function Questionnaire (NEI-VFQ) SST Report Number 19. Ophthalmic Epidemiol 14 (2007) 205-215
25. Brown G.C. Vision and quality-of-life. Trans Am Ophthalmol Soc 97 (1999) 473-511
26. Chakravarthy U., and Stevenson M. Self-reported visual functioning and quality of life in age-related macular degeneration. Curr Opin Ophthalmol 16 (2005) 179-183
27. Espallargues M., Czoski-Murray C.J., Bansback N.J., et al. The impact of age-related macular degeneration on health status utility values. Invest Ophthalmol Vis Sci 46 (2005) 4016-4023
28. World Health Organization. Constitution of the World Health Organization. Basic Documents. 45th ed. (October 2006). http://www.who.int/governance/eb/who_constitution_en.pdf Accessed October 7, 2009
29. Brazier J., Roberts J., Tsuchiya A., and Busschbach J. A comparison of the EQ-5D and the SF-6D across seven patient groups. Health Econ 13 (2004) 873-884
30. Feeny D., Furlong W., Torrance G.W., et al. Multiattribute and single-attribute utility functions for the Health Utilities Index Mark 3 system. Med Care 40 (2002) 113-128
31. Stevens K.J., McCabe C.J., and Brazier J.E. Mapping between Visual Analogue Scale and Standard Gamble data: results from the UK Health Utilities Index 2 valuation survey. Health Econ 15 (2007) 527-533
32. Browne J., Jamieson L., Lewsey J., et al. Patient Reported Outcome Measures (PROMs) in elective surgery: Report to the Department of Health. http://www.lshtm.ac.uk/hsru/research/PROMs-Report-12-Dec-07.pdf Accessed October 4, 2009
33. Griffin S.C., Barber J.A., Manca A., et al. Cost effectiveness of clinically appropriate decisions on alternative treatments for angina pectoris: prospective observational study. BMJ 334 (2007) 624